66.85

0.01% -0.01

After Hours: 66.85

Disc Medicine Inc (IRON)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Disc Medicine Inc stock is traded at $66.85, with a volume of 582.18K. It is down -0.01% in the last 24 hours and down -6.86% over the past month. Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

Previous Close:

$66.86

Open:

$69.725

24h Volume:

582.18K

Relative Volume:

0.89

Market Cap:

$2.55B

Revenue:

Net Income/Loss:

$-212.18M

P/E Ratio:

-11.16

EPS:

-5.9897

Net Cash Flow:

$-181.33M

1W Performance:

-3.44%

1M Performance:

-6.86%

6M Performance:

-25.51%

1Y Performance:

+39.01%

1-Day Range:

$65.78

$69.72

1-Week Range:

$65.78

$72.35

52-Week Range:

$40.00

$99.50

Disc Medicine Inc Stock (IRON) Company Profile

Name

Disc Medicine Inc

Sector

Healthcare (1109)

Industry

Biotechnology (612)

Phone

(617) 674-9274

Address

321 ARSENAL STREET, SUITE 101, WATERTOWN

Employee

155

Twitter

Next Earnings Date

2026-05-06

Latest SEC Filings

IRON's Discussions on Twitter

Compare IRON vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IRON Disc Medicine Inc	66.85	2.55B	0	-212.18M	-181.33M	-5.9897
VRTX Vertex Pharmaceuticals Inc	436.58	110.90B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	629.68	73.20B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	776.26	49.71B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	286.27	38.32B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	144.37	30.97B	742.00K	-1.37B	-1.07B	-7.0731

Disc Medicine Inc Stock (IRON) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-03-25	Resumed	Stifel	Buy
Jul-21-25	Initiated	Truist	Buy
Jul-03-25	Resumed	Morgan Stanley	Overweight
Jun-11-25	Resumed	Raymond James	Strong Buy
Feb-27-25	Initiated	TD Cowen	Buy
Nov-05-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-04-24	Upgrade	Raymond James	Outperform → Strong Buy
Oct-23-24	Initiated	Jefferies	Buy
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-22-24	Initiated	Wells Fargo	Overweight
Apr-01-24	Downgrade	Raymond James	Strong Buy → Outperform
Dec-19-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-09-23	Upgrade	Raymond James	Outperform → Strong Buy
Jun-07-23	Initiated	H.C. Wainwright	Buy
May-17-23	Initiated	Raymond James	Outperform
Apr-28-23	Initiated	Cantor Fitzgerald	Overweight
Apr-21-23	Initiated	Stifel	Buy
Apr-20-23	Initiated	Morgan Stanley	Overweight
Mar-23-23	Initiated	BMO Capital Markets	Outperform
Feb-28-23	Initiated	SVB Securities	Outperform

View All

Disc Medicine Inc Stock (IRON) Latest News

05:27 AM

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - Carroll County Mirror-Democrat

05:27 AM

May 17, 2026

UBS Group AG Reduces Holdings in Disc Medicine, Inc. $IRON - MarketBeat

May 17, 2026

May 16, 2026

Should Disc Medicine’s RALLY-MF Data and Wider Pipeline Reveal a Pivotal Inflection for IRON’s Narrative? - simplywall.st

May 16, 2026

May 15, 2026

Morgan Stanley Raises Price Target on Disc Medicine to $80 From $75, Keeps Overweight Rating - marketscreener.com

May 14, 2026

May 13, 2026

Understanding Momentum Shifts in (IRON) - Stock Traders Daily

May 13, 2026

IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are ... - Caledonian Record

May 13, 2026

IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.

May 13, 2026

May 12, 2026

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inqui - GuruFocus

May 12, 2026

Disc Medicine, Inc. Announces Oral Presentation of Phase 2 RALLY-MF Trial Data for DISC-0974 at EHA 2026 Congress and Corporate Update Call - Quiver Quantitative

May 12, 2026

Experimental anemia treatment shows 70% response in myelofibrosis trial - Stock Titan

May 12, 2026

Vanguard Group Inc. Acquires 319,621 Shares of Disc Medicine, Inc. $IRON - MarketBeat

May 12, 2026

May 11, 2026

Stifel Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $111 - Moomoo

May 11, 2026

Hear Disc Medicine leaders in two live investor conference webcasts - Stock Titan

May 11, 2026

Disc Medicine to Participate in Upcoming Investor Conferences - FinancialContent

May 11, 2026

Number of shareholders of Disc Medicine, Inc. – NASDAQ:IRON - TradingView

May 11, 2026

May 10, 2026

A Look At Disc Medicine (IRON) Valuation As Key APOLLO Phase 3 And Pipeline Milestones Progress - Sahm

May 10, 2026

May 09, 2026